Nguyen Thuy, Coover Robert A, Verghese Jenson, Moran Richard G, Ellis Keith C
Department of Medicinal Chemistry, School of Pharmacy, and the Massey Cancer Center, Virginia Commonwealth University , Richmond, Virginia 23298-0540, United States.
Department of Pharmacology & Toxicology, School of Medicine, and the Massey Cancer Center, Virginia Commonwealth University , Richmond, Virginia 23298-0540, United States.
ACS Med Chem Lett. 2014 Mar 7;5(5):462-7. doi: 10.1021/ml500088x. eCollection 2014 May 8.
Strategies to inhibit kinases by targeting the substrate binding site offer many advantages, including naturally evolved selectivity filters, but normally suffer from poor potency. In this work we propose a strategy to design and prepare covalent substrate-competitive kinase inhibitors as a method to improve potency. We have chosen AKT as the model kinase for this work. Using the AKT-GSK3β cocrystal structure and a reactive cysteine near the substrate binding site, we have identified phenylalanine (Phe) as an appropriate scaffold for the covalent inactivator portion of these inhibitors. By synthesizing compounds that incorporate cysteine-reactive electrophiles into phenylalanine and testing these compounds as AKT inhibitors, we have identified Boc-Phe-vinyl ketone as a submicromolar inactivator of AKT. We also show that Boc-Phe-vinyl ketone (1) potently inhibits AKT1 and inhibits cell growth in HCT116 and H460 cells nearly as well as AKT inhibitors GSK690693 and MK-2206, (2) is selective for kinases that possess an activation loop cysteine such as AKT, (3) requires the vinyl ketone for inactivation, (4) has inactivation that is time-dependent, and (5) alkylates Cys310 of AKT as shown by mass spectrometry. Identification of Boc-Phe-vinyl ketone as a covalent inactivator of AKT will allow the development of peptide and small-molecule substrate-competitive covalent kinase inhibitors that incorporate additional substrate binding elements to increase selectivity and potency. This proof-of-principle study also provides a basis to apply this strategy to other kinases of the AGC and CAMK families.
通过靶向底物结合位点来抑制激酶的策略具有诸多优势,包括天然进化出的选择性过滤器,但通常效力不佳。在这项工作中,我们提出一种设计和制备共价底物竞争性激酶抑制剂的策略,以此作为提高效力的方法。我们选择AKT作为这项工作的模型激酶。利用AKT - GSK3β共晶体结构以及底物结合位点附近的一个反应性半胱氨酸,我们确定苯丙氨酸(Phe)是这些抑制剂共价失活部分的合适支架。通过合成将半胱氨酸反应性亲电试剂引入苯丙氨酸的化合物,并将这些化合物作为AKT抑制剂进行测试,我们确定Boc - Phe - 乙烯基酮是一种亚微摩尔级的AKT失活剂。我们还表明,Boc - Phe - 乙烯基酮(1)能有效抑制AKT1,并几乎与AKT抑制剂GSK690693和MK - 2206一样有效地抑制HCT116和H460细胞的生长,(2)对具有激活环半胱氨酸的激酶如AKT具有选择性,(3)失活需要乙烯基酮,(4)失活具有时间依赖性,并且(5)如质谱所示,使AKT的Cys310烷基化。鉴定出Boc - Phe - 乙烯基酮作为AKT的共价失活剂将有助于开发包含额外底物结合元件以提高选择性和效力的肽和小分子底物竞争性共价激酶抑制剂。这项原理验证研究也为将该策略应用于AGC和CAMK家族的其他激酶提供了基础。